Addiction

Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia

Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain

Opioid-free and addiction-free pain treatment therapy could address $1.5B worldwide CINP marketATLANTA, March 18, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics,...

Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs

NYC Building & Construction Industry Safety Fund program will equip local workers, contractors and staff with NARCAN® Nasal Spray and...

Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program

Reiterates Planned Cytisinicline NDA Submission Expected at the End of Q2 2025 Company to Host Conference Call at 8:30 AM...

Drs. Jeffrey Lieberman, M.D. and David Sinclair, Ph.D. to Present ‘The New Frontier of Longevity Science: Living Well Beyond Your Years’ at SXSW 2025

World-leading authorities explore the potential for extending human lifespan on Monday, March 10 at the JW Marriott AustinAUSTIN, Texas, March 07,...

Achieve Life Sciences to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call and Webcast on March 11, 2025

SEATTLE and VANCOUVER, British Columbia, March 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty...

Bicycle Health & Wellpath Sign Additional 1-Year Contract with Federal Bureau of Prisons (FBOP) to Continue Opioid Use Disorder Treatment for Patients in Community Placements

This telehealth-based treatment program started in 2023 and has treated over 2600 patients, allowing them to continue treatment after release,...

Protega Pharmaceuticals collaborates with Wellgistics Health to support pharmacist education and increase patient access to the first and only FDA-approved abuse-deterrent immediate-release opioid, ROXYBOND™

ROXYBOND, formulated with patented, first-of-its-kind abuse-deterrent technology SentryBond™, is designed to provide multiple levels of protection PRINCETON, N.J., March 3, 2025...

error: Content is protected !!